Nakamizo et al. demonstrated through in vivo and in vitro experiments that MSCs derived from bone marrow can migrate to tumor sites and, when injected adjacent to glioma xenografts, could home effectively to the tumor (in an HGF-dependent mechanism), interact and integrate with glioma cells, and inhibit their growth [34,35]. Here, HGF is linked to central nervous system cancer.